Gimatecan and other camptothecin derivatives poison Leishmania DNA-topoisomerase IB leading to a strong leishmanicidal effect

Biochemical Pharmacology

Volumn 85, Issue 10, 2013, Pages 1433-1440

  Prada, Christopher F ^a   Álvarez Velilla, Raquel ^a   Balaña Fouce, Rafael ^a   Prieto, Carlos ^b   Calvo Álvarez, Estefania ^a   Escudero Martínez, Jose Miguel ^a   Requena, José María ^c   Ordóñez, César ^a   Desideri, Alessandro ^d   Pérez Pertejo, Yolanda ^a   Reguera, Rosa M ^a  

^a UNIVERSITY OF LEÓN   (Spain)

^b Institute of Biotechnology INBIOTEC Parque Científico de León   (Spain)

^c CENTRO DE BIOLOGÍA MOLECULAR SEVERO OCHOA   (Spain)

^d UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Camptothecin; DNA topoisomerase IB; Gimatecan; Leishmania spp; Splenic explants

Indexed keywords

ANTILEISHMANIAL AGENT; CAMPOTOTHECIN N OXIDE; CAMPTOTHECIN CARBOXYLATE; CAMPTOTHECIN DERIVATIVE; CAMPTOTHECIN LACTONE; DNA TOPOISOMERASE; DNA TOPOISOMERASE IB; FIRTECAN; GIMATECAN; HYCANTIM; IRINOTECAN; MILTEFOSINE; TOPOTECAN; UNCLASSIFIED DRUG;

AMASTIGOTE; ANIMAL CELL; ARTICLE; CELL GROWTH; CONTROLLED STUDY; DNA PROTEIN COMPLEX; DNA SUPERCOILING; DRUG EFFICACY; EX VIVO STUDY; IN VITRO STUDY; LEISHMANIA INFANTUM; NONHUMAN; PRIORITY JOURNAL; PROMASTIGOTE; SPLEEN CELL; VISCERAL LEISHMANIASIS;

ANIMALS; ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; CELLS, CULTURED; DNA TOPOISOMERASES, TYPE I; GENES, REPORTER; INHIBITORY CONCENTRATION 50; KINETICS; LEISHMANIA INFANTUM; LIFE CYCLE STAGES; LUMINESCENT PROTEINS; MICE; PRODRUGS; PROTOZOAN PROTEINS; SPLEEN; TOPOISOMERASE I INHIBITORS; TRYPANOCIDAL AGENTS;

EID: 84876668143     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2013.02.024     Document Type: Article

References (30)

1. I. Cruz, J. Nieto, J. Moreno, C. Cañavate, P. Desjeux, and J. Alvar Leishmania/HIV co-infections in the second decade Indian J Med Res 123 2006 357 388
2. J. Berman Clinical status of agents being developed for leishmaniasis Expert Opin Investig Drugs 14 2005 1337 1346
3. S.L. Croft, and P. Olliaro Leishmaniasis chemotherapy-challenges and opportunities Clin Microbiol Infect 17 2011 1478 1483
4. J.J. Champoux DNA topoisomerases: structure, function, and mechanism Annu Rev Biochem 70 2001 369 413
5. Y. Pommier Topoisomerase I inhibitors: camptothecins and beyond Nat Rev Cancer 6 2006 789 802
6. H. Villa, A.R. Otero-Marcos, R.M. Reguera, R. Balaña-Fouce, C. García-Estrada, and Y. Pérez-Pertejo A novel active DNA topoisomerase I in Leishmania donovani J Biol Chem 278 2003 3521 3526
7. A.L. Bodley, A.K. Chakraborty, S. Xie, C. Burri, and T.A. Shapiro An unusual type IB topoisomerase from African trypanosomes Proc Natl Acad Sci USA 100 2003 7539 7544
8. R. Balaña-Fouce, C.M. Redondo, Y. Pérez-Pertejo, R. Díaz-González, and R.M. Reguera Targeting atypical trypanosomatid DNA topoisomerase I Drug Discov Today 11 2006 733 740
9. R. Díaz-González, Y. Pérez-Pertejo, D. Ordóñez, R. Balaña-Fouce, and R.M. Reguera Deletion study of DNA topoisomerase IB from Leishmania donovani: searching for a minimal functional heterodimer PLoS ONE 2 2007 e1177
10. C.F. Prada, R. Alvarez-Velilla, R. Diaz-González, C. Prieto, Y. Pérez-Pertejo, and R. Balaña-Fouce A pentapeptide signature motif plays a pivotal role in Leishmania DNA topoisomerase IB activity and camptothecin sensitivity Biochim Biophys Acta 1820 2012 2062 2071
11. R.P. Hertzberg, M.J. Caranfa, and S.M. Hecht On the mechanism of topoisomerase I inhibition by camptothecin: evidence for binding to an enzyme-DNA complex Biochemistry 28 1989 4629 4638
12. B.L. Staker, K. Hjerrild, M.D. Feese, C.A. Behnke, A.B. Burgin Jr., and L. Stewart The mechanism of topoisomerase I poisoning by a camptothecin analog Proc Natl Acad Sci USA 99 2002 15387 15392
13. M.J. Luzzio, J.M. Besterman, D.L. Emerson, M.G. Evans, K. Lackey, and P.L. Leitner Synthesis and antitumor activity of novel water soluble derivatives of camptothecin as specific inhibitors of topoisomerase I J Med Chem 38 1995 395 401
14. S. Antony, K.K. Agama, Z.H. Miao, M. Hollingshead, S.L. Holbeck, and M.H. Wright Bisindenoisoquinoline bis-1,3-{(5,6-dihydro-5,11-diketo-11H-indeno[1,2- c]isoquinoline)-6-propylamino}propane bis(trifluoroacetate) (NSC 727357), a DNA intercalator and topoisomerase inhibitor with antitumor activity Mol Pharmacol 70 2006 1109 1120
15. A.B. Teicher Next generation topoisomerase I inhibitors: rationale and biomarker strategies Biochem Pharmacol 75 2008 1262 1271
16. M.P. Lee, S.D. Brown, A. Chen, and T.S. Hsieh DNA topoisomerase I is essential in Drosophila melanogaster Proc Natl Acad Sci USA 90 1993 6656 6660
17. R. Balaña-Fouce, C. Garcia-Estrada, Y. Perez-Pertejo, and R.M. Reguera Gene disruption of the DNA topoisomerase IB small subunit induces a non-viable phenotype in the hemoflagellate Leishmania major BMC Microbiol 8 2008 113
18. R.P. Bakshi, and T.A. Shapiro RNA interference of Trypanosoma brucei topoisomerase IB: both subunits are essential Mol Biochem Parasitol 136 2004 249 255
19. R.M. Reguera, C.M. Redondo, R. Gutierrez de Prado, Y. Pérez-Pertejo, and R. Balaña-Fouce DNA topoisomerase I from parasitic protozoa: a potential target for chemotherapy Biochim Biophys Acta 1759 2006 117 131
20. R. Balaña-Fouce, C.F. Prada, J.M. Requena, M. Cushman, Y. Pommier, and R. Álvarez-Velilla Indotecan (LMP400) and AM13-55: two novel indenoisoquinolines show potential for treating visceral leishmaniasis Antimicrob Agents Chemother 56 2012 5264 5270
21. X. Shu, A. Royant, M.Z. Lin, T.A. Aguilera, V. Lev-Ram, and P.A. Steinbach Mammalian expression of infrared fluorescent proteins engineered from a bacterial phytochrome Science 324 2009 804 807
22. Y. Osorio, B.L. Travi, A.R. Rensio, A.G. Peniche, and P.C. Melby Identification of small molecule lead compounds for visceral leishmaniasis using novel ex vivo splenic explant model system Plos Negl Trop Dis 5 2011 e962
23. T.S. Dexheimer, and Y. Pommier DNA cleavage assay for the identification of topoisomerase I inhibitors Nat Protoc 3 2008 1736 1749
24. A. Tanizawa, A. Fujimori, Y. Fujimori, and Y. Pommier Comparison of topoisomerase I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials J Natl Cancer Inst 86 1994 836 842
25. M. Valenti, W. Nieves-Neira, G. Kohlhagen, K.W. Kohn, M.E. Wall, and M.C. Wani Novel 7-alkyl methylenedioxy-camptothecin derivatives exhibit increased cytotoxicity and induce persistent cleavable complexes both with purified mammalian topoisomerase I and in human colon carcinoma SW620 cells Mol Pharmacol 52 1997 82 87
26. G.H. Coombs, D.T. Hart, and J. Capaldo Leishmania mexicana: drug sensitivities of promastigotes and transforming amastigotes J Antimicrob Chemother 11 1983 151 162
27. S. Dallavalle, T. Delsoldato, A. Ferrari, L. Merlini, S. Penco, and N. Carenini Novel 7-substituted camptothecins with potent antitumor activity J Med Chem 43 2000 3963 3969
28. A.X. Zhu, N. Ready, J.W. Clark, H. Safran, A. Amato, and N. Salem Phase I and pharmacokinetic study of gimatecan given orally once a week for 3 of 4 weeks in patients with advanced solid tumors Clin Cancer Res. 15 2009 374 381
29. T.G. Burke, C.B. Munshi, Z. Mi, and Y. Jiang The important role of albumin in determining the relative human blood stabilities of the camptothecin anticancer drugs J Pharm Sci 84 1995 518 519
30. T.P. Dorlo, P.P. van Thiel, A.D. Huitema, R.J. Keizer, H.J. de Vries, and J.H. Beijnen Pharmacokinetics of miltefosine in Old World cutaneous leishmaniasis patients Antimicrob Agents Chemother 52 2008 2855 2860